Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio in patients with glioblastoma

  • Authors:
    • Özlem Yersal
    • Eylem Odabaşi
    • Özge Özdemir
    • Yasemin Kemal
  • View Affiliations

  • Published online on: August 9, 2018     https://doi.org/10.3892/mco.2018.1695
  • Pages: 453-458
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. Identification of accessible and cost‑effective prognostic factors may better guide adjuvant treatment‑related decisions. The neutrophil‑to‑lymphocyte ratio (NLR) and platelet‑to‑lymphocyte ratio (PLR) are markers of host inflammatory response, and their increase has recently been shown to be a poor prognostic factor in several malignancies. The aim of the present study was to investigate the prognostic value of preoperative NLR and PLR in GBM patients. Between 2012 and 2017, 104 patients who had undergone surgery for GBM were considered for adjuvant therapy in our institution. Of those, 80 patients with evaluable pre‑corticosteroid full blood count results were identified and included in the final analysis. The Eastern Cooperative Oncology Group performance status, localization, radiochemotherapy and second‑line systemic therapy were found to be independent prognostic indicators for progression‑free and overall survival. The median overall survival was 13.2 months. Patients with NLR <4 had a better median overall survival of 10.7 vs. 7.8 months in patients with NLR >4; however, this difference was not statistically significant (P>0.05). Overall survival also did not differ significantly between patients with low and those with high PLR values (10.2 vs. 15.2 months, respectively; P=0.105). In conclusion, the results of the present study suggest that pre‑treatment NLR and PLR do not have prognostic value in GBM patients; however, large‑scale trials are required to confirm these findings.
View Figures
View References

Related Articles

Journal Cover

October 2018
Volume 9 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yersal, Ö., Odabaşi, E., Özdemir, Ö., & Kemal, Y. (2018). Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio in patients with glioblastoma. Molecular and Clinical Oncology, 9, 453-458. https://doi.org/10.3892/mco.2018.1695
MLA
Yersal, Ö., Odabaşi, E., Özdemir, Ö., Kemal, Y."Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio in patients with glioblastoma". Molecular and Clinical Oncology 9.4 (2018): 453-458.
Chicago
Yersal, Ö., Odabaşi, E., Özdemir, Ö., Kemal, Y."Prognostic significance of pre‑treatment neutrophil‑to‑lymphocyte ratio and platelet‑to‑lymphocyte ratio in patients with glioblastoma". Molecular and Clinical Oncology 9, no. 4 (2018): 453-458. https://doi.org/10.3892/mco.2018.1695